All In Biotech

Drug Trial Radar · NCT05714202

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,135 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,135

Actual

Start

Mar 23, 2023

Primary completion

Sep 18, 2029

Study completion Sep 18, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).

Conditions

  • Bladder Cancer

Interventions

  • TAR-200Drug

    TAR-200 will be administered intravesically.

  • CetrelimabBiological

    Cetrelimab will be administered.

  • BCG VesicultureBiological

    BCG will be administered intravesically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS)Time frame: Up to 5 years 2 months

Locations

240 sites in 21 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • Arkansas Urology

    Little Rock, Arkansas

  • VA Long Beach Health Care System

    Long Beach, California

  • Genesis Research, LLC - West Coast Urology

    Los Alamitos, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Genesis Research

    San Diego, California

  • Providence Saint Johns Cancer Institute

    Santa Monica, California

  • Providence Medical Foundation

    Santa Rosa, California

  • Colorado Clinical Research

    Lakewood, Colorado

  • Urological Research Network

    Hialeah, Florida

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • Grady Memorial Hospital

    Atlanta, Georgia

  • The Emory Clinic Department of Urology

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Duly Health and Care

    Lisle, Illinois

  • Blessing Hospital

    Quincy, Illinois

  • Urology of Indiana

    Carmel, Indiana

  • First Urology

    Jeffersonville, Indiana

  • AMR Kansas City Oncology

    Merriam, Kansas

  • Wichita Urology Group

    Wichita, Kansas

  • Chesapeake Urology Research Associates

    Hanover, Maryland

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • University Of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • The Urology Center, PC

    Omaha, Nebraska

  • Cooper Health System MD Anderson Cancer Center at Cooper

    Camden, New Jersey

  • VA NY Harbor Healthcare System

    New York, New York

  • Icahn School of Medicine at Mt. Sinai

    New York, New York

  • Associated Medical Professionals of Ny

    Syracuse, New York

  • SUNY Upstate Med Univ

    Syracuse, New York

  • Vidant Urology - Greenville

    Greenville, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Central Ohio Urology Group

    Gahanna, Ohio

  • Centers for Advanced Urology LLC d b a MidLantic Urology

    Bala-Cynwyd, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • UPMC Shadyside Hospital

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.